Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended in December - Earnings Summary
14/02/2024 17:14
* Sonnet Biotherapeutics Holdings Inc SONN.OQ reported a
quarterly adjusted loss of 31 cents per share for the quarter
ended in December, higher than the same quarter last year, when
the company reported EPS of $-17.60. The mean expectation of
three analysts for the quarter was for a loss of 90 cents per
share. Wall Street expected results to range from -94 cents
to -86 cents per share.
* Revenue was $18.63 thousand; analysts expected $18.00
thousand.
* Sonnet Biotherapeutics Holdings Inc's reported EPS for the
quarter was a loss of 31 cents.
* The company reported a quarterly loss of $1.17 million.
* Sonnet Biotherapeutics Holdings Inc shares had fallen
by 11.2%
this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 52.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is "buy."
Wall Street's median 12-month price target for Sonnet
Biotherapeutics Holdings Inc is $32.50
This summary was machine generated from LSEG data February 14 at
05:14 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.90 -0.31 Beat
Sep. 30 2023 -4.09 -2.09 Beat
Jun. 30 2023 -6.82 -2.86 Beat
Mar. 31 2023 -10.89 -7.48 Beat